



**Dr. Reddy's Laboratories Ltd.**  
8-2-337, Road No. 3, Banjara Hills  
Hyderabad – 500 034, Telangana, India  
CIN: L85195TG1984PLC004507  
Tel: + 91 40 4900 2900  
Fax: + 91 40 4900 2999  
Email: [mail@drreddys.com](mailto:mail@drreddys.com)  
Web: [www.drreddys.com](http://www.drreddys.com)

October 29, 2025

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)  
BSE Limited (Scrip Code: 500124)  
New York Stock Exchange Inc. (Stock Code: RDY)  
NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

**Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We have received a Notice of Non-Compliance (NON) from Pharmaceutical Drugs Directorate, Canada, regarding our Abbreviated New Drug Submission (ANDS) for Semaglutide Injection. The NON outlines requests for additional information & clarifications on specific aspects of the submission. We will submit a response at the earliest and well within the stipulated time period.

We remain confident in the quality, safety and comparability of our proposed product and remain committed to making this important therapy available to patients in Canada and other markets at the earliest. We appreciate the continued support of our stakeholders and will share further updates as appropriate.

This is for your information and record.

Thanking you.

Yours faithfully,

**For Dr. Reddy's Laboratories Limited**

**K Randhir Singh**  
*Company Secretary, Compliance Officer & Head-CSR*